202 related articles for article (PubMed ID: 36476658)
21. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
22. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
23. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
24. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
[TBL] [Abstract][Full Text] [Related]
25. Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
Li Y; Jaiswal SK; Kaur R; Alsaadi D; Liang X; Drews F; DeLoia JA; Krivak T; Petrykowska HM; Gotea V; Welch L; Elnitski L
BMC Cancer; 2021 Jul; 21(1):768. PubMed ID: 34215221
[TBL] [Abstract][Full Text] [Related]
26. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
McLachlan J; Gore M; Banerjee S
Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
[TBL] [Abstract][Full Text] [Related]
28. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
[TBL] [Abstract][Full Text] [Related]
29. Hormone receptor expression profile of low-grade serous ovarian cancers.
Buttarelli M; Mascilini F; Zannoni GF; Ciucci A; Martinelli E; Filippetti F; Scambia G; Ferrandina G; Gallo D
Gynecol Oncol; 2017 May; 145(2):352-360. PubMed ID: 28228232
[TBL] [Abstract][Full Text] [Related]
30.
D'Ambrosio C; Erriquez J; Arigoni M; Capellero S; Mittica G; Ghisoni E; Borella F; Katsaros D; Privitera S; Ribotta M; Maldi E; Di Nardo G; Berrino E; Venesio T; Ponzone R; Vaira M; Hall D; Jimenez-Linan M; Paterson AL; Calogero RA; Brenton JD; Valabrega G; Di Renzo MF; Olivero M
Cells; 2020 Feb; 9(2):. PubMed ID: 32075097
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics in low-grade serous ovarian cancer.
Cobb L; Gershenson D
Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
[TBL] [Abstract][Full Text] [Related]
32. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
34. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
37. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
38. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S; Kennedy JJ; Ivey RG; Murillo OD; Hosseini N; Song X; Petralia F; Calinawan A; Savage SR; Berry AB; Reva B; Ozbek U; Krek A; Ma W; da Veiga Leprevost F; Ji J; Yoo S; Lin C; Voytovich UJ; Huang Y; Lee SH; Bergan L; Lorentzen TD; Mesri M; Rodriguez H; Hoofnagle AN; Herbert ZT; Nesvizhskii AI; Zhang B; Whiteaker JR; Fenyo D; McKerrow W; Wang J; Schürer SC; Stathias V; Chen XS; Barcellos-Hoff MH; Starr TK; Winterhoff BJ; Nelson AC; Mok SC; Kaufmann SH; Drescher C; Cieslik M; Wang P; Birrer MJ; Paulovich AG
Cell; 2023 Aug; 186(16):3476-3498.e35. PubMed ID: 37541199
[TBL] [Abstract][Full Text] [Related]
39. Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Tholander B; Koliadi A; Botling J; Dahlstrand H; Von Heideman A; Ahlström H; Öberg K; Ullenhag GJ
Ups J Med Sci; 2020 Nov; 125(4):325-329. PubMed ID: 33043759
[TBL] [Abstract][Full Text] [Related]
40. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Spreafico A; Oza AM; Clarke BA; Mackay HJ; Shaw P; Butler M; Dhani NC; Lheureux S; Wilson MK; Welch S; Zhang T; Yu C; Stockley T; Siu LL; Kamel-Reid S; Bedard PL
Gynecol Oncol; 2017 Feb; 144(2):250-255. PubMed ID: 28062115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
